Literature DB >> 12499213

Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.

Lanfranco Fattorini1, Dejiang Tan, Elisabetta Iona, Maurizio Mattei, Federico Giannoni, Lara Brunori, Simona Recchia, Graziella Orefici.   

Abstract

The activity of moxifloxacin was enhanced by the addition of ethionamide but not by that of cycloserine, thiacetazone, capreomycin, para-aminosalicylic acid, or linezolid in BALB/c mice infected with a strain of Mycobacterium tuberculosis resistant to isoniazid, rifampin, and six other drugs. These observations are important for the therapy of multidrug-resistant tuberculosis.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12499213      PMCID： PMC149032          DOI： 10.1128/AAC.47.1.360-362.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy.

Authors:  G Pozzi; M Meloni; E Iona; G Orrù; O F Thoresen; M L Ricci; M R Oggioni; L Fattorini; G Orefici
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

2.  The treatment of multidrug-resistant tuberculosis in Turkey.

Authors:  K Tahaoğlu; T Törün; T Sevim; G Ataç; A Kir; L Karasulu; I Ozmen; N Kapakli
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

3.  Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.

Authors:  M H Cynamon; S P Klemens; C A Sharpe; S Chase
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis.

Authors:  L Fattorini; E Iona; M L Ricci; O F Thoresen; G Orrù; M R Oggioni; E Tortoli; C Piersimoni; P Chiaradonna; M Tronci; G Pozzi; G Orefici
Journal:  Microb Drug Resist       Date:  1999       Impact factor: 3.431

5.  Experimental comparative study of the concentration of cycloserine in the serum and viscera in conventional laboratory animals and in the monkey.

Authors:  P J Coletsos
Journal:  Scand J Respir Dis Suppl       Date:  1970

6.  Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.

Authors:  Tetsuyuki Yoshimatsu; Eric Nuermberger; Sandeep Tyagi; Richard Chaisson; William Bishai; Jacques Grosset
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.

Authors:  Enrique J Alvirez-Freites; Janna L Carter; Michael H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

8.  In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Authors:  B Ji; N Lounis; C Maslo; C Truffot-Pernot; P Bonnafous; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

9.  Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo.

Authors:  C Jagannath; H S Allaudeen; R L Hunter
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

10.  Therapy of multidrug-resistant tuberculosis: lessons from studies with mice.

Authors:  S P Klemens; M S DeStefano; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191
View more
  11 in total

1.  Novel conjugate of moxifloxacin and carboxymethylated glucan with enhanced activity against Mycobacterium tuberculosis.

Authors:  Y S Schwartz; M I Dushkin; V A Vavilin; E V Melnikova; O M Khoschenko; V A Kozlov; A P Agafonov; A Y Alekseev; Y Rassadkin; A M Shestapalov; M S Azaev; D V Saraev; P N Filimonov; Y Kurunov; A V Svistelnik; V A Krasnov; A Pathak; S C Derrick; R C Reynolds; S Morris; V M Blinov
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 2.  Current development and future prospects in chemotherapy of tuberculosis.

Authors:  Eric L Nuermberger; Melvin K Spigelman; Wing Wai Yew
Journal:  Respirology       Date:  2010-06-04       Impact factor: 6.424

3.  d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Authors:  Devyani Deshpande; Jan-Willem C Alffenaar; Claudio U Köser; Keertan Dheda; Moti L Chapagain; Noviana Simbar; Thomas Schön; Marieke G G Sturkenboom; Helen McIlleron; Pooi S Lee; Thearith Koeuth; Stellah G Mpagama; Sayera Banu; Suporn Foongladda; Oleg Ogarkov; Suporn Pholwat; Eric R Houpt; Scott K Heysell; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

4.  Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model.

Authors:  Elise D Pieterman; Lindsey H M Te Brake; Gerjo J de Knegt; Aart van der Meijden; Jan-Willem C Alffenaar; Hannelore I Bax; Rob E Aarnoutse; Jurriaan E M de Steenwinkel
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

5.  Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.

Authors:  Nacer Lounis; Nicolas Veziris; Aurélie Chauffour; Chantal Truffot-Pernot; Koen Andries; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

6.  Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis.

Authors:  Federico Giannoni; Elisabetta Iona; Federica Sementilli; Lara Brunori; Manuela Pardini; Giovanni Battista Migliori; Graziella Orefici; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

7.  Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.

Authors:  K N Williams; C K Stover; T Zhu; R Tasneen; S Tyagi; J H Grosset; E Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

8.  Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.

Authors:  Dorothee Heemskerk; Jeremy Day; Tran Thi Hong Chau; Nguyen Huy Dung; Nguyen Thi Bich Yen; Nguyen Duc Bang; Laura Merson; Piero Olliaro; Thomas Pouplin; Maxine Caws; Marcel Wolbers; Jeremy Farrar
Journal:  Trials       Date:  2011-02-02       Impact factor: 2.279

9.  Successful Treatment of Disseminated Bacillus Calmette-Guérin Disease in an HIV-Infected Child with a Linezolid-Containing Regimen.

Authors:  Srđan Roglić; Drusia Dickson; Branko Miše; Klaudija Višković; Vera Katalinić-Janković; George Rutherford; Josip Begovac
Journal:  Case Rep Infect Dis       Date:  2016-10-10

10.  Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis.

Authors:  Samantha Donnellan; Ghaith Aljayyoussi; Emmanuel Moyo; Alison Ardrey; Carmen Martinez-Rodriguez; Stephen A Ward; Giancarlo A Biagini
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.